| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9922710.0AGB9922710D0 (en) | 1999-09-24 | 1999-09-24 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis |
| JP2001526163AJP2003510272A (en) | 1999-09-24 | 2000-09-12 | Use of substituted 4-biarylbutyric acid and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| EP00965974AEP1217994A2 (en) | 1999-09-24 | 2000-09-12 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| PCT/EP2000/008890WO2001022951A2 (en) | 1999-09-24 | 2000-09-12 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| AU76536/00AAU7653600A (en) | 1999-09-24 | 2000-09-12 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| CA002385490ACA2385490A1 (en) | 1999-09-24 | 2000-09-12 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9922710.0AGB9922710D0 (en) | 1999-09-24 | 1999-09-24 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis |
| Publication Number | Publication Date |
|---|---|
| GB9922710D0true GB9922710D0 (en) | 1999-11-24 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB9922710.0ACeasedGB9922710D0 (en) | 1999-09-24 | 1999-09-24 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis |
| Country | Link |
|---|---|
| EP (1) | EP1217994A2 (en) |
| JP (1) | JP2003510272A (en) |
| AU (1) | AU7653600A (en) |
| CA (1) | CA2385490A1 (en) |
| GB (1) | GB9922710D0 (en) |
| WO (1) | WO2001022951A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2832633B1 (en)* | 2001-11-28 | 2004-09-24 | Lipha | PHARMACEUTICAL COMPOSITION COMPRISING A METFORMIN ASSOCIATION AND A 4-OXO-BUTANOIC ACID AND ITS USE FOR TREATING DIABETES |
| FR2832927A1 (en)* | 2001-12-03 | 2003-06-06 | Lipha | PHARMACEUTICAL COMPOSITION COMPRISING A 4-OXO-BUTANOIC ACID AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF DIABETES |
| FR2834214B1 (en)* | 2001-12-28 | 2004-09-24 | Lipha | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND 4-OXO-BUTANOIC ACID AND ITS USE FOR TREATING DIABETES |
| FR2834640B1 (en)* | 2002-01-11 | 2004-09-24 | Lipha | PHARMACEUTICAL COMPOSITION COMPRISING A GLITAZONE AND A 4-OXOBUTANOIC ACID AND ITS USE FOR TREATING DIABETES |
| US7842791B2 (en)* | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| CN103086947A (en)* | 2011-11-04 | 2013-05-08 | 赵庆春 | Phthalimide compounds with antiangiogenic activity and purpose thereof |
| CN113185447B (en)* | 2021-05-06 | 2023-07-21 | 四川大学 | Phthalylcysteine compounds, their preparation methods and uses |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5789434A (en)* | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| TNSN97083A1 (en)* | 1996-05-15 | 2005-03-15 | Bayer Corp | INHIBITION OF METALLOPROTEASE MATRICES BY SUBSTITUTION OF OXOBUTYRIC BIARYL ACID |
| US6288063B1 (en)* | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
| Publication number | Publication date |
|---|---|
| AU7653600A (en) | 2001-04-30 |
| WO2001022951A3 (en) | 2001-10-11 |
| EP1217994A2 (en) | 2002-07-03 |
| JP2003510272A (en) | 2003-03-18 |
| WO2001022951A2 (en) | 2001-04-05 |
| CA2385490A1 (en) | 2001-04-05 |
| Publication | Publication Date | Title |
|---|---|---|
| HUP0104425A3 (en) | Anthranilic acid amides and the use thereof for the treatment of angiogenesis | |
| IL187030A0 (en) | Use of retigabine for the treatment of neuropathic pain | |
| MXPA02004770A (en) | Therapeutic compositions and methods of use thereof. | |
| AU4205100A (en) | Methods and compositions for the treatment of pancreatitis | |
| KR100510795B1 (en) | Compositions and Methods for the Treatment of Tumor | |
| IL136110A0 (en) | Methods and compositions for the treatment of psoriasis | |
| GB2367103B (en) | Connector and method of use of the connector | |
| HUP0200738A3 (en) | Method of the treatment of incontinence | |
| GB9929497D0 (en) | Improved amino acid mixtures for the treatment and/or management of certain diseases | |
| GB9922710D0 (en) | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis | |
| IL133760A0 (en) | Composition for the treatment of dandruff | |
| IL144115A0 (en) | Use of phosphororganic compounds for the prophylactic and therapeutical treatment of infections | |
| AU2566201A (en) | Compounds and methods for the treatment of pain | |
| AU2420101A (en) | Method and composition for the treatment of pain | |
| GB0014356D0 (en) | Treatment of multiple sclerosis | |
| IL143795A0 (en) | Use of 3-isoxazolidinones and hydroxylamic acids for the treatment of infections | |
| PL350963A1 (en) | Use of arylalkanoylpyridazines | |
| GB9904252D0 (en) | Composition for the treatment of pain | |
| IL150202A0 (en) | Method and composition for the treatment of pain | |
| AU4116500A (en) | The use of alpha lipoic acid in the antimetastatic treatment | |
| IL150208A0 (en) | Compound and method for the treatment of pain | |
| GB9817348D0 (en) | Pharmaceutical use of esters | |
| AU2420201A (en) | Compounds and methods for the treatment of pain | |
| KR100511819B1 (en) | Compositions and Methods for the Treatment of Tumor | |
| IL136687A0 (en) | Pharmaceutical composition for the treatment of multiple sclerosis |
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |